

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A10/2017 WB

DESPATCHED ON 03RD OCTOBER 2017

HLA PHENOTYPE OF BLOOD DONOR: A1, A2; B8, B63; Cw1, Cw7; DR1, DR4; DQ5, DQ7

				Summary of Results												
				PBL				T-Cells				B-Cells				
				7	8	8	9	17	17	17	17	16	15	15	15	
				3	0	0	1	2	0	0	0	13	4	12	6	
				4	8	8	8	15	17	17	17	3	11	3	9	
				3	2	2	1	3	3	3	3	5	6	6	6	
				42.9%	0.0%	0.0%	11.1%	11.8%	0.0%	0.0%	0.0%	81.3%	26.7%	80.0%	40.0%	
				57.1%	100.0%	100.0%	88.9%	88.2%	100.0%	100.0%	100.0%	18.8%	73.3%	20.0%	60.0%	
Consensus				Not Assessed	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Not Assessed	Positive	Not Assessed	
HLA Antibody Specificity (Defined By CDC)				DR5 DR6 DQ6	DQ3	B7 DR2	Multi	DR5 DR6 DQ6	DQ3	B7 DR2	Multi	DR5 DR6 DQ6	DQ3	B7 DR2	Multi	
				Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
9	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability
11	YES	YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	B-cell results not reported due to poor viability
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
20	YES		YES	Positive	Negative	Negative	Negative					NT	NT	NT	NT	B cell testing not possible due to dynabead product recall and on going validation of new B cell separation technique
23		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Samples were two days old on receipt. Condition of cells precluded confident analysis. A technical problem relating to Dynabead separation was also encountered and is under review
24		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
25		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Equivocal	Negative	
28		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Poor B-cell viability
34		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
35	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative					
38	YES	YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
39		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
41		YES	YES					Positive	Negative	Negative	Negative	NT	NT	NT	NT	Samples went missing after delivery
42	YES	YES	YES	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Positive	Negative	Positive	Negative	
45		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	Poor B-cell viability
51		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Positive	Positive	The quality of the cells was very poor.
54		YES	YES					Negative	Negative	Negative	Negative	Positive	Equivocal	Positive	Equivocal	
58		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
117	YES			Equivocal	Equivocal	Equivocal	Negative									Low viability. Weak positive reactions may have been lost. In our routine, we would have requested a repeat sample.
136		YES						Negative	Negative	Negative	Negative					
149	YES			Equivocal	Negative	Negative	Negative					Negative	Negative	Negative	Positive	
205	YES		YES	Negative	Negative	Negative	Positive					Negative	Negative	Positive	Positive	
212		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
311		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
315		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A10/2017 WB

DESPATCHED ON 03RD OCTOBER 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	10	15	10
11	2	-	-	-	-	-	-	-	NT	NT	NT	NT	85	95	40
12	1	1	1	1	1	1	11		8	4	6	4	90	90	90
20	2	1	1	1					NT	NT	NT	NT	90		
23					NT	NT	NT	NT	NT	NT	NT	NT			
24					20	10	10	10	90	40	80	60		90	70
25					1	1	1	1	6	1	4	1		95	90
28					1	1	1	1	2	1	2	1		95	85
34					1	1	1	1	8	2	6	1		95	92
35	1	1	1	1	1	1	1	1					80	40	
38	2	1	1	1	1	1	1	1	8	1	2	1	90	98	95
39					2	-	-	-	8	4	6	2		95	95
41					NT	NT	NT	NT	NT	NT	NT	NT			
42	<10	<10	<10	<10					>80	<10	60-80	<10	95		85
45					1	1	1	1	8	1	6	1		99	70
51					1-2	0	0	0	8	2	6	4		95	90
54					11-20	10-30	11-20	11-20	200	31-40	61-70	41-50		90	70
58					10	5	5	5	90	10	70	10		95	15
117	Equivocal	Equivocal	Equivocal	-									70		
136					1	1	1	1						98	
149	Equivocal	-	-	-									70		
205	-	-	-	++					-	-	-	++	80		80
212					-	-	-	-	-	-	-	-		100	100
311					1	1	1	1	6	1	4	2		100	80
315					1	1	1	1	6	1	6	1		90	80

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A10/2017 WB

DESPATCHED ON 03RD OCTOBER 2017

HLA PHENOTYPE OF BLOOD DONOR: A1, A2; B8, B63; Cw1, Cw7; DR1, DR4; DQ5, DQ7

				Summary of Results												
				PBL				T-Cells				B-Cells				
				7	8	8	8	16	16	16	16	16	16	16	16	
Total tested				3	0	0	1	1	0	0	0	11	2	2	2	
Positive				4	8	8	7	15	16	16	16	5	14	14	14	
Negative				2	1	1	1	2	2	2	2	4	4	4	4	
NT/Equivocal				42.9%	0.0%	0.0%	12.5%	6.3%	0.0%	0.0%	0.0%	68.8%	12.5%	12.5%	12.5%	
% Positive				57.1%	100.0%	100.0%	87.5%	93.8%	100.0%	100.0%	100.0%	31.3%	87.5%	87.5%	87.5%	
% Negative																
Consensus				Not Assessed	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Not Assessed	Negative	Negative	Negative	
HLA Antibody Specificity (Defined By CDC)				DR5 DR6 DQ6	DQ3	B7 DR2	Multi	DR5 DR6 DQ6	DQ3	B7 DR2	Multi	DR5 DR6 DQ6	DQ3	B7 DR2	Multi	
				With DTT				With DTT				With DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
9	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability B-cell results not reported due to poor viability
11	YES	YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	B cell testing not possible due to dynabead product recall and on going validation of new B cell separation technique
15	YES	YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
20	YES		YES	Positive	Negative	Negative	Negative					NT	NT	NT	NT	
24		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Poor B-cell viability
25		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
34		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
35	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative					
38	YES	YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
39		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
41		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	
42	YES		YES	Negative	Negative	Negative	Negative					Positive	Negative	Negative	Negative	
45		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
51		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
58		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
149	YES			Equivocal	Negative	Negative	Negative									
205	YES		YES	Negative	Negative	Negative	Positive					Negative	Negative	Negative	Positive	
212		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
311		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
315		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A10/2017 WB

DESPATCHED ON 03RD OCTOBER 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	10	15	10
11	2	-	-	-	-	-	-	-	NT	NT	NT	NT	85	95	40
12	1	1	1	1	1	1	1	1	8	4	4	4	90	90	90
15					0	0	0	0	0	0	1	0	100	100	100
20	2	1	1	1					NT	NT	NT	NT	90		
24					10	10	10	10	90	40	40	40		90	70
25					1	1	1	1	1	1	1	1		95	90
28					1	1	1	1	2	1	1	1		95	85
34					1	1	1	1	8	1	1	1		95	92
35	1	1	1	1	1	1	1	1					80	40	
38	2	1	1	1	1	1	1	1	8	1	1	1	90	98	95
39					-	-	-	-	6	-	-	-		95	95
41					NT	NT	NT	NT	NT	NT	NT	NT			
42	<10	<10	<10	<10					>80	<10	<10	<10	95		85
45					1	1	1	1	6	1	1	1		99	70
51					2	0	0	0	8	2	0	0		95	90
58					5	5	5	5	90	15	15	15		95	15
149	Equivocal	-	-	-									70		
205	-	-	-	++					-	-	-	++	80		80
212					-	-	-	-	-	-	-	-		100	100
311					1	1	1	1	6	1	1	1		100	80
315					1	1	1	1	6	1	1	1		90	80